Paul Smith

Paul Smith

Company: Incyte Corporation

Job title: Senior Director - Pharmacology (Non- Oncology)


Paul Smith currently works as the Senior Director of Preclinical Pharmacology within the Incyte Research Institute (Incyte Corporation) with a focus on autoimmune and inflammatory diseases.  Dr. Smith received his PhD in Immunology from Imperial College London (University of London) and subsequently completed post-doctoral training at the Biomedical Primate Research Center (the Netherlands). Since 2005 Dr Smith has held positions of increasing responsibility at UCB, Merck Serono and Novartis before joining Incyte Corporation in early 2017.  Dr Smith’s research focus has encompassed preclinical in vitro and in vivo approaches to identify potential novel therapeutic modalities for inflammatory diseases and facilitate rapid transition into proof-of-concept trials. Ultimately this scientific approach has contributed towards conference presentations, peer-reviewed publications, patents and regulatory approved therapies for inflammatory diseases. 


Live Q&A 10:40 am

Using this opportunity to ask your expert speakers those burning questions.Read more

day: Day Two

Pharmacological Targeting of PI3 Kinase Delta in B-Cell Driven Autoimmune Diseases 9:10 am

Explain the biological relevance of targeting PI3 kinase (PI3K)delta in B-cell driven autoimmunity Outline the drug discovery story of Parsaclisib (INCB050465), a highly selective small molecule PI3Kdelta inhibitor Describe the key biochemical, cellular and preclinical model data that supported clinical trials with Parsaclisib (INCB050465) in autoimmune indicationsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.